WallStreetZenWallStreetZen

NASDAQ: CLGN
COLLPLANT BIOTECHNOLOGIES LTD Stock Forecast, Predictions & Price Target

Should I buy or sell CLGN stock?

Based on 1 analyst offering ratings for COLLPLANT BIOTECHNOLOGIES LTD.
Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Forecast return on equity

Is CLGN forecast to generate an efficient return?
Company
107.54%
Industry
78.79%
Market
31.09%
CLGN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CLGN forecast to generate an efficient return on assets?
Company
95.34%
Industry
21.24%
CLGN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CLGN earnings per share forecast

What is CLGN's earnings per share in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
-$0.38
Avg 2 year Forecast
$3.19
Avg 3 year Forecast
$3.06

CLGN revenue forecast

What is CLGN's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$11.9M+885.92%
Avg 2 year Forecast
$70.6M+5,752.53%
Avg 3 year Forecast
$106.1M+8,690.39%
CLGN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CLGN revenue growth forecast

How is CLGN forecast to perform vs Biotechnology companies and vs the US market?
Company
344.63%
Industry
17.98%
Market
9.17%
CLGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CLGN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CLGN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CLGN$9.51N/AN/AStrong Buy
CTMX$1.62$10.75+563.58%Strong Buy
SESN$0.53N/AN/AHold
ETTX$2.19$3.15+44.16%Hold
SURF$1.91N/AN/AStrong Buy

COLLPLANT BIOTECHNOLOGIES Stock Forecast FAQ

Is COLLPLANT BIOTECHNOLOGIES Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: CLGN) stock is to Strong Buy CLGN stock.

Out of 1 analyst, 1 (100%) are recommending CLGN as a Strong Buy, 0 (0%) are recommending CLGN as a Buy, 0 (0%) are recommending CLGN as a Hold, 0 (0%) are recommending CLGN as a Sell, and 0 (0%) are recommending CLGN as a Strong Sell.

What is CLGN's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: CLGN) COLLPLANT BIOTECHNOLOGIES's current Earnings Per Share (EPS) is -$1.34. On average, analysts forecast that CLGN's EPS will be -$0.38 for 2022, with the lowest EPS forecast at -$0.38, and the highest EPS forecast at -$0.38. On average, analysts forecast that CLGN's EPS will be $3.19 for 2023, with the lowest EPS forecast at $3.19, and the highest EPS forecast at $3.19. In 2024, CLGN's EPS is forecast to hit $3.06 (min: $3.06, max: $3.06).

What is CLGN's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: CLGN) forecast ROE is 107.54%, which is considered strong.

What is CLGN's earnings growth forecast for 2022-2024?

(NASDAQ: CLGN) COLLPLANT BIOTECHNOLOGIES's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 7.19%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.67%.

COLLPLANT BIOTECHNOLOGIES's earnings in 2022 is -$13,747,000.On average, 1 Wall Street analyst forecast CLGN's earnings for 2022 to be -$4,212,863, with the lowest CLGN earnings forecast at -$4,212,863, and the highest CLGN earnings forecast at -$4,212,863. On average, 1 Wall Street analyst forecast CLGN's earnings for 2023 to be $35,365,874, with the lowest CLGN earnings forecast at $35,365,874, and the highest CLGN earnings forecast at $35,365,874.

In 2024, CLGN is forecast to generate $33,924,632 in earnings, with the lowest earnings forecast at $33,924,632 and the highest earnings forecast at $33,924,632.

What is CLGN's revenue growth forecast for 2022-2024?

(NASDAQ: CLGN) COLLPLANT BIOTECHNOLOGIES's forecast annual revenue growth rate of 344.63% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 17.98%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 9.17%.

COLLPLANT BIOTECHNOLOGIES's revenue in 2022 is $1,207,000.On average, 1 Wall Street analysts forecast CLGN's revenue for 2022 to be $131,929,124, with the lowest CLGN revenue forecast at $131,929,124, and the highest CLGN revenue forecast at $131,929,124. On average, 1 Wall Street analysts forecast CLGN's revenue for 2023 to be $783,149,018, with the lowest CLGN revenue forecast at $783,149,018, and the highest CLGN revenue forecast at $783,149,018.

In 2024, CLGN is forecast to generate $1,176,275,634 in revenue, with the lowest revenue forecast at $1,176,275,634 and the highest revenue forecast at $1,176,275,634.

What is CLGN's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: CLGN) forecast ROA is 95.34%, which is higher than the forecast US Biotechnology industry average of 21.24%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.